Coupling of aggregation and immunogenicity in biotherapeutics: T- and B-cell immune epitopes may contain aggregation-prone regions

Atomic structures of amyloid cross-β spines reveal varied steric zippers

Sawaya, M. R., Sambashivan, S., Nelson, R. A., Ivanova, M. I., Sievers, S. A., Apostol, M. I., Thompson, M. J., Balbirnie, M., Wiltzius, J. J. W., McFarlane, H. T., et al. (2007) · Nature · doi:10.1038/nature05695 · Cited by 2,279 · see citing works

Structure of the cross-β spine of amyloid-like fibrils

Nelson, R. A., Sawaya, M. R., Balbirnie, M., Madsen, A. Ø., Riekel, C., Grothe, R., & Eisenberg, D. S. (2005) · Nature · doi:10.1038/nature03680 · Cited by 2,205 · see citing works

3D structure of Alzheimer's amyloid-β(1–42) fibrils

Lührs, T., Ritter, C., Adrian, M., Riek-Loher, D., Bohrmann, B., Döbeli, H., Schubert, D. A., & Riek, R. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506723102 · Cited by 2,001 · see citing works

Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins

Fernández‐Escamilla, A. M., Rousseau, F., Schymkowitz, J. W. H., & Serrano, L. G. (2004) · Nature Biotechnology · doi:10.1038/nbt1012 · Cited by 1,663 · see citing works

A semi‐empirical method for prediction of antigenic determinants on protein antigens

Kolaskar, A. S., & Tongaonkar, P. (1990) · FEBS Letters · doi:10.1016/0014-5793(90)80535-q · Cited by 1,493 · see citing works

Effects of protein aggregates: An immunologic perspective

Rosenberg, A. S. (2006) · The AAPS Journal · doi:10.1208/aapsj080359 · Cited by 1,355 · see citing works

The immunogenicity of humanized and fully human antibodies

Harding, F., Stickler, M. M., Razo, J., & DuBridge, R. B. (2010) · mAbs · doi:10.4161/mabs.2.3.11641 · Cited by 743 · see citing works

Exploring the sequence determinants of amyloid structure using position-specific scoring matrices

Maurer‐Stroh, S., Debulpaep, M., Kuemmerer, N., de la Paz, M. L., Martins, I. C., Reumers, J., Morris, K. L., Copland, A., Serpell, L. C., Serrano, L. G., et al. (2010) · Nature Methods · doi:10.1038/nmeth.1432 · Cited by 682 · see citing works

The immune epitope database 2.0

Vita, R., Zarebski, L., Greenbaum, J. A., Emami, H., Hoof, I., Salimi, N., Damle, R., Sette, A., & Peters, B. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkp1004 · Cited by 631 · see citing works

Design of therapeutic proteins with enhanced stability

Chennamsetty, N., Voynov, V., Kayser, V., Helk, B., & Trout, B. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904191106 · Cited by 597 · see citing works

Overlooking Subvisible Particles in Therapeutic Protein Products: Gaps That May Compromise Product Quality

Carpenter, J. F., Randolph, T. W., Jiskoot, W., Crommelin, D. J. A., Middaugh, C. R., Winter, G., Fan, Y., Kirshner, S., Verthelyi, D. I., Kozlowski, S., et al. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21530 · Cited by 597 · see citing works

Recent atomic models of amyloid fibril structure

Nelson, R. A., & Eisenberg, D. S. (2006) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2006.03.007 · Cited by 393 · see citing works

Activation of natural regulatory T cells by IgG Fc–derived peptide “Tregitopes”

Groot, A. S. D., Moise, L., McMurry, J. A., Wambre, E. R., Overtvelt, L. V., Moingeon, P. E., Scott, D. W., & Martin, W. D. (2008) · Blood · doi:10.1182/blood-2008-02-138073 · Cited by 392 · see citing works

Impact of Product-Related Factors on Immunogenicity of Biotherapeutics

Singh, S. K. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22276 · Cited by 350 · cited 6× · see citing works

Antibody humanization: a case of the ‘Emperor’s new clothes’?

Clark, M., & Clark, M. (2000) · Immunology Today · doi:10.1016/s0167-5699(00)01680-7 · Cited by 259 · see citing works

Safety-Related Regulatory Actions for Biologicals Approved in the United States and the European Union

Giezen, T. J., Mantel-Teeuwisse, A. K., Straus, S. M. J. M., Schellekens, H., Leufkens, H. G. M., & Egberts, T. C. G. (2008) · JAMA · doi:10.1001/jama.300.16.1887 · Cited by 258 · see citing works

Engineering of therapeutic antibodies to minimize immunogenicity and optimize function

Presta, L. G. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.01.026 · Cited by 247 · see citing works

Towards a consensus on datasets and evaluation metrics for developing B-cell epitope prediction tools

Greenbaum, J. A., Andersen, P. H., Blythe, M., Bui, H., Cachau, R. E., Crowe, J., Davies, M., Kolaskar, A. S., Lund, O., Morrison, S., et al. (2007) · Journal of Molecular Recognition · doi:10.1002/jmr.815 · Cited by 244 · see citing works

Bacterial Inclusion Bodies Contain Amyloid-Like Structure

Wang, L., Maji, S. K., Sawaya, M. R., Eisenberg, D. S., & Riek, R. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060195 · Cited by 230 · see citing works

Prediction of aggregation rate and aggregation‐prone segments in polypeptide sequences

Tartaglia, G. G., Cavalli, A., Pellarin, R., & Caflisch, A. (2005) · Protein Science · doi:10.1110/ps.051471205 · Cited by 214 · see citing works

Structure−Function Engineering of Interferon-β-1b for Improving Stability, Solubility, Potency, Immunogenicity, and Pharmacokinetic Properties by Site-Selective Mono-PEGylation

Basu, A., Yang, K., Wang, M., Liu, S., Chintala, R., Palm, T., Zhao, H., Peng, P., Wu, D., Zhang, Z., et al. (2006) · Bioconjugate Chemistry · doi:10.1021/bc050322y · Cited by 213 · see citing works

The crystal structure of human interferon β at 2.2-Å resolution

Karpusas, M., Nolte, M. C., Benton, C. B., Meier, W., Lipscomb, W. N., & Goelz, S. E. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.22.11813 · Cited by 211 · see citing works

Immunological mechanism underlying the immune response to recombinant human protein therapeutics

Sauerborn, M., Brinks, V., Jiskoot, W., & Schellekens, H. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.11.001 · Cited by 207 · see citing works

Potential aggregation prone regions in biotherapeutics: A survey of commercial monoclonal antibodies

Wang, X., Das, T. K., Singh, S. K., & Kumar, S. (2009) · mAbs · doi:10.4161/mabs.1.3.8035 · Cited by 198 · see citing works

Antibody Response to Aggregated Human Interferon Alpha2b in Wild-type and Transgenic Immune Tolerant Mice Depends on Type and Level of Aggregation

Hermeling, S., Schellekens, H., Maas, C., Gebbink, M. F. B. G., Crommelin, D. J. A., & Jiskoot, W. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20599 · Cited by 185 · see citing works

Immunogenicity of aggregates of recombinant human growth hormone in mouse models

Fradkin, A. H., Carpenter, J. F., & Randolph, T. W. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21834 · Cited by 170 · see citing works

Physicochemical principles that regulate the competition between functional and dysfunctional association of proteins

Pechmann, S., Levy, E. D., Tartaglia, G. G., & Vendruscolo, M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812414106 · Cited by 159 · see citing works

A Role for Protein Misfolding in Immunogenicity of Biopharmaceuticals

Maas, C., Hermeling, S., Bouma, B., Jiskoot, W., & Gebbink, M. F. B. G. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605984200 · Cited by 157 · see citing works

Aggregation-Prone Motifs in Human Immunoglobulin G

Chennamsetty, N., Helk, B., Voynov, V., Kayser, V., & Trout, B. L. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.06.028 · Cited by 156 · see citing works

What Drives Amyloid Molecules To Assemble into Oligomers and Fibrils?

Schmit, J. D., Ghosh, K., & Dill, K. A. (2011) · Biophysical Journal · doi:10.1016/j.bpj.2010.11.041 · Cited by 139 · see citing works

Naturally Processed HLA Class II Peptides Reveal Highly Conserved Immunogenic Flanking Region Sequence Preferences That Reflect Antigen Processing Rather Than Peptide-MHC Interactions

Godkin, A. J., Smith, K. J., Willis, A., Tejada-Simon, M. V., Zhang, J., Elliott, T. J., & Hill, A. V. S. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6720 · Cited by 125 · see citing works

Nonnative Aggregation of an IgG1 Antibody in Acidic Conditions: Part 1. Unfolding, Colloidal Interactions, and Formation of High-Molecular-Weight Aggregates

Brummitt, R. K., Nesta, D. P., Chang, L., Chase, S. F., Laue, T. M., & Roberts, C. J. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22448 · Cited by 125 · see citing works

Protein Formulation and Delivery

(2007) · CRC Press eBooks · doi:10.3109/9780849379529 · Cited by 110 · see citing works

Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates

DEGROOT, A., MCMURRY, J., & MOISE, L. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.08.002 · Cited by 109 · see citing works

Aggregation of therapeutic proteins

Wang, W., & Roberts, C. J. (2010) · Wiley eBooks · Cited by 104 · see citing works

Prediction of Immunogenicity of Therapeutic Proteins

Bryson, C. J., Jones, T. D., & Baker, M. (2010) · BioDrugs · doi:10.2165/11318560-000000000-00000 · Cited by 102 · see citing works

Untitled work

(2007) · PubMed · Cited by 100 · see citing works

Clinical link between MHC class II haplotype and interferon-beta (IFN-β) immunogenicity

Barbosa, M. D. F. S., Vielmetter, J., Chu, S. Y., Smith, D. D., & Jacinto, J. M. (2005) · Clinical Immunology · doi:10.1016/j.clim.2005.08.017 · Cited by 99 · see citing works

Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A

Lacroix‐Desmazes, S., Navarrete, A., André, S., Bayry, J., Kaveri, S. V., & Dasgupta, S. (2008) · Blood · doi:10.1182/blood-2008-02-124941 · Cited by 95 · see citing works

Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII

JONES, T. D., Phillips, W. J., Smith, B. J., BAMFORD, C. A., Nayee, P. D., Baglin, T. P., Gaston, H., & Baker, M. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01309.x · Cited by 90 · see citing works

Potential aggregation-prone regions in complementarity-determining regions of antibodies and their contribution towards antigen recognition: a computational analysis

Wang, X., Singh, S. K., & Kumar, S. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0143-5 · Cited by 79 · see citing works

Asparagine Deamidation Perturbs Antigen Presentation on Class II Major Histocompatibility Complex Molecules

Moss, C., Matthews, S. P., Lamont, D. J., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501241200 · Cited by 74 · see citing works

β Edge strands in protein structure prediction and aggregation

Siepen, J. A., Radford, S. E., & Westhead, D. R. (2003) · Protein Science · doi:10.1110/ps.03234503 · Cited by 57 · see citing works

Aggregation and Immunogenicity of Therapeutic Proteins

Filipe, V., Hawe, A., Schellekens, H., & Jiskoot, W. (2010) · doi:10.1002/9780470769829.ch10 · Cited by 39 · see citing works

mAb therapeutic products and risk management

Reichert, J. M. (2010) · mAbs · doi:10.4161/mabs.2.1.10628 · Cited by 28 · see citing works

Identification and Impact of Aggregation‐Prone Regions in Proteins and Therapeutic Monoclonal Antibodies

Kumar, S., Wang, X., & Singh, S. K. (2010) · doi:10.1002/9780470769829.ch3 · Cited by 24 · see citing works

The formulation and immunogenicity of therapeutic proteins: Product quality as a key factor.

Richard, J., & Prang, N. (2010) · PubMed · Cited by 18 · see citing works

Preclinical Safety Evaluation of Monoclonal Antibodies

Lynch, C. M., & Grewal, I. S. (2007) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-73259-4_2 · Cited by 15 · see citing works

Fundamental Structures and Behaviors of Proteins

Laurence, J. S., & Middaugh, C. R. (2010) · Wiley eBooks · doi:10.1002/9780470769829.ch1 · Cited by 14 · see citing works

5th European Antibody Congress 2009

Beck, A., Reichert, J. M., & Wurch, T. (2010) · mAbs · doi:10.4161/mabs.2.2.11302 · Cited by 12 · see citing works

Preclinical safety evaluation of monoclonal antibodies

Foulkes, R. (2002) · Toxicology · doi:10.1016/s0300-483x(02)00053-7 · Cited by 11 · see citing works

Temperature‐Dependent Molecular Adaptations, Microbial Proteins

Kumar, S., Singh, S. K., & Gromiha, M. M. (2010) · Wiley eBooks · doi:10.1002/9780470054581.eib516 · Cited by 9 · see citing works

Computational approaches to therapeutic antibody design: established methods and emerging trends

Norman, R. A., Ambrosetti, F., Bonvin, A. M. J. J., Colwell, L. J., Kelm, S., Kumar, S., & Krawczyk, K. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbz095 · Cited by 219 · see citing works

Anti-drug antibodies: emerging approaches to predict, reduce or reverse biotherapeutic immunogenicity

Pratt, K. P. (2018) · Antibodies · doi:10.3390/antib7020019 · Cited by 96 · see citing works

In vitro models for immunogenicity prediction of therapeutic proteins

Groell, F., Jordan, O., & Borchard, G. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.06.008 · Cited by 53 · see citing works

Relationship between potential aggregation-prone regions and HLA-DR-binding T-cell immune epitopes: implications for rational design of novel and follow-on therapeutic antibodies

Kumar, S., Mitchell, M. A., Rup, B., & Singh, S. K. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23169 · Cited by 33 · see citing works

Fine specificity of the B-cell epitopes recognized in HIV-1 NEF by human sera

Tähtinen, M., Gombert, F. O., Hyytinen, E., et al. (1992) · Virology · doi:10.1016/0042-6822(92)90304-8 · Cited by 6 · see citing works

Immunogenicity of Therapeutic Proteins

Swanson, S. J. (2010) · doi:10.1002/9780470595886.ch4 · Cited by 29 · see citing works

Immunogenicity

Galson, J. D., & O’Connor, D. (2015) · Encyclopedia of Life Sciences · doi:10.1002/9780470015902.a0000937

Induction of High Levels of Antibodies Recognizing the Neutralizing Epitope ELDKWA and the D- or K-Position-Mutated Epitopes by Candidate Epitope Vaccines against HIV-1

Xiao, Y. Q., Dong, X., & Chen, Y. (2000) · International Archives of Allergy and Immunology · doi:10.1159/000024411 · Cited by 7 · see citing works

Mapping of 10 epitopes on bovine herpesvirus type 1 glycoproteins gl and glll

Fitzpatrick, D. R., Redmondz, M. J., ATTAH‐POKU, S. K., et al. (1990) · Virology · doi:10.1016/0042-6822(90)90239-n · Cited by 34 · see citing works